SCHEMBL31486145

SCHEMBL31486145

O=C(O)c1cc(Br)cn(C2CC2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.44
LMNA P02545 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
NOTUM Q6P988 1/20 0.39
HSD17B10 Q99714 2/20 0.38
GAA P10253 1/20 0.38
PIK3CD O00329 1/20 0.38
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CG P48736 1/20 0.38
AKR1C3 P42330 2/20 0.37
AKR1C2 P52895 2/20 0.37
AKR1C4 P17516 1/20 0.37
AKR1C1 Q04828 1/20 0.37
TOP2A P11388 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31485983 0.85 MEN1 (0.43) KDM4EALDH1A1HPGDLMNAMEN1
SCHEMBL31286511 0.81 OPRK1 (0.42) KDM4EALDH1A1HPGDLMNAMEN1
SCHEMBL31485880 0.78 NOTUM (0.37) KDM4EALDH1A1HPGDLMNAMEN1
SCHEMBL31286519 0.76 NOTUM (0.36) KDM4EALDH1A1HPGDLMNAMEN1
SCHEMBL24724127 0.74 LMNA (0.36) KDM4EALDH1A1HPGDLMNAMEN1
SCHEMBL16651414 0.74 L3MBTL1 (0.36) KDM4EALDH1A1HPGDLMNAMEN1
SCHEMBL3374696 0.72 MAP2K1 (0.45) KDM4EMEN1KMT2AHSD17B10AKR1C3
SCHEMBL32680245 0.71 HSD17B10 (0.39) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL17156871 0.71 KDM4E (0.41) KDM4EALDH1A1HPGDLMNAMEN1
SCHEMBL29576694 0.69 KDM4E (0.59) KDM4EALDH1A1HPGDLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116868-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-04-30 US disclosed
WO-2025076299-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116868-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBLC, CBL KDM4E 2320/4885ALDH1A1 3286/4885HPGD 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.